Executive Officers
Yun Li, CEO

Yun Li, Ph.D., Chief Executive Officer of Nob Hill Therapeutics and Managing Director of VIC Technology Venture Development’s New Mexico Branch. Dr. Li’s multifaceted professional career spans from R&D and global program management in Fortune 500 companies to technology commercialization/startup and business consulting. In 2006, she started a consulting firm in business and professional development. In this capacity, she has assisted a wide range of companies in building commercialization strategies and capabilities, clarifying value propositions, defining applications/markets, building teams, and raising capital. She is a founding member of five technology startups. Dr. Li is an advocate for international collaboration in technology commercialization and is deeply immersed in the US-China collaboration ecosystem. She was a board member of Startup New Mexico, and serves on the board of advisors at Technology Venture Corporation. Dr. Li graduated from Tsinghua University, China, with a B.S. in EE and a M.S. in Nuclear Physics. She received her Ph.D in Materials Science from Arizona State University.


James Hannon, CTO

James Hannon, Chief Technology Officer.  Mr. Hannon has an extensive background in the development of inhaled drug delivery devices from his 13+ year career in product development for multiple inhalation drug delivery startups and large pharmas. He was integral to the design and development of MAP Pharmaceuticals Levodex Inhaler which was later acquired by Allergan for $958 million.  More recently, he was leading the design and development of Respira Therapeutics novel dry powder inhaler AOS™ which was subsequently funded for development by United Therapeutics. Mr. Hannon has an extensive background in the design and development of all major inhalation delivery technologies including nebulizers, MDIs, and dry powder inhalers. He holds a B.S. degree in Bioengineering from the University of California, San Diego.




Board of Directors
Calvin Goforth, Chairman

Calvin Goforth, Ph.D., Chairman of the Board, is Founder and Chief Executive Officer of VIC Technology Venture Development, Inc. Dr. Goforth has extensive experience in start-up company development in founder, investor, board member, and executive roles. His experience encompasses intellectual property assessment, building strong development teams, raising private investment and government funding, and bringing products to market. He received a B.S. in Aerospace Engineering with Highest Honors from the University of Texas at Austin. Early in his career, Dr. Goforth held positions at NASA (where he worked alternate semesters while pursuing his B.S.) and Rocketdyne, where he worked in the space shuttle main engine performance analysis group. He later received his Ph.D. in Mechanical Engineering with a minor in Electrical Engineering from Stanford University. He then returned to his home state of Arkansas and took a position as an Assistant Professor in Mechanical Engineering at the University of Arkansas. There, he received the school’s Halliburton Outstanding Researcher Award in Mechanical Engineering for three straight years. He left his faculty position to form Vector, Inc. with the vision to build open-architecture PC-based controllers. He self-financed the company and developed its first product in one year. Product sales ramped up quickly and the company was sold at the end of its second year of operations. Dr. Goforth’s experiences with Vector and other early stage technology companies led him to found Virtual Incubation Company (now VIC Technology Venture Development). At VIC he developed the company’s virtual enterprising business model to support the formation and development of technology start-up companies. Dr. Goforth also founded and manages the VIC Investor Network that provides seed capital into every new company VIC forms.


Jee Shin, Director

Jee Shin, Director and Managing Director VIC Technology Venture Development’s California Branch. Ms. Shin is serving as interim CEO of Kalera Medical. Ms. Shin has over 20 years of healthcare industry experience, including over 12 years at ProQuest Investments, a healthcare venture capital firm with approximately $900M under management. During her tenure at ProQuest, Ms. Shin invested and managed fifteen private and public healthcare companies, eight of which successfully exited. Prior to joining ProQuest, Ms. Shin served as the Director of Marketing and Business Development at Situs Corporation, a venture-backed developer of drug delivery systems. Previously, she served as a Marketing Associate at Guidant and as a Surgical Specialist at Johnson & Johnson. Ms. Shin received a B.A. in International Studies with a concentration in International Trade and Investment from the University of Washington and an M.B.A. from the Stanford Graduate School of Business.


In addition to Dr. Goforth and Ms. Shin, above, Dr. Yun Li is a director on the Nob Hill Therapeutics board.


Board of Advisors
David Harris

is a global leading expert in inhalation device design and development, and aerosol science. His specialties include dry powder inhaler (DPI) design and development; aerosol physics, electrostatics, and fluid dynamics; cyclone and separation system design; and, mathematical and analytical modeling. Mr. Harris is advising Nob Hill on inhalation drug device design and engineering.

Oleh Hnatiuk, M.D.

is a professor with the University of New Mexico School of Medicine, and has over thirty years’ experience in pulmonary medicine and patient care. He is certified in Internal Medicine, Pulmonary Medicine, Sleep Medicine, and Critical Care Medicine.  Dr. Hnatiuk is advising the company in the areas of pulmonary and infectious medicine, as well as patient advocacy.

Matthew Reed, Ph.D.

is Principal and Owner of Coelus LLC, where he facilitates early to late phase development of pharmaceutical IP and provides consulting services in integrated drug development strategies, toxicology, pharmacology, and hazard assessment. Dr. Reed is a pharmacologist, board certified toxicologist, ABT Board Member, and Fellow of the Academy of Toxicology Sciences (ATS).  Dr. Reed is advising Nob Hill on grant development and clinical trials.








Comments are closed.